2025-524857-15-00招募中1 期
A Multicenter, Open-Label, Phase 1a/b First-in-Human Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of BG-C0979 in Patients with Selected Advanced Solid Tumors
BeOne Medicines I GmbH4 个研究点 分布在 1 个国家目标入组 24 人开始时间: 2026年5月7日最近更新:
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 发起方
- 入组人数
- 24
- 试验地点
- 4
研究概览
简要总结
暂无简介。
入排标准
- 年龄范围
- 18 years 至 65+ years（18-64 Years, 65+ Years）
- 接受健康志愿者
- 否
入选标准
- 未提供
排除标准
- 未提供
研究者
BeOne Medical Officer
Scientific
BeOne Medicines I GmbH
研究点 (4)
Loading locations...
相似试验
招募中
不适用
BG-C477-101Advanced Solid TumorsjRCT203125086018
招募中
不适用
Anti-Ly6E Exatecan ADC M7437 in Advanced Solid TumorsAdvanced Solid TumorsjRCT203125067815
尚未招募
1 期
A Phase 1, Single-Center, Open-Label, Fixed-Sequence, 2-Part Study to Assess the Pharmacokinetics of IMU-838 Administered Alone and in Combination with Multiple Doses of Gemfibrozil as CYP2C8 Inhibitor, or Rifampicin as CYP2C8 Inducer, in Healthy SubjectsMultiple sclerosis2025-521754-41-00Immunic AG24
招募中
不适用
A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Standard of Care in Participants With Relapsed-Refractory Multiple Myeloma (RRMM) (DREAMM-15)relapsed-refractory multiple myelomajRCT206125010140
招募中
不适用
A Study of TAK-226 for Anemia in Japanese Patients with Lower-Risk Myelodysplastic SyndromesMyelodysplastic syndromesjRCT203125060342